Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Eli Lilly reported strong year-over-year revenue growth in the second quarter of 2026 and said its full-year guidance now slightly exceeds market expectations, following a period of accelerating demand for its key therapies.
THE APEX TIMES
THE APEX TIMES
The company says patients may gain access to its next weight-loss therapy before a final FDA decision, as Lilly prepares to submit its approval request early next year.
THE APEX TIMES
In a fresh Q2 2026 investor letter highlighted by Yahoo Finance, Baron Capital frames Eli Lilly’s obesity franchise as the sector’s standard-bearer, even as competition and pricing pressure remain open questions for the $150 billion market it references.
THE APEX TIMES
The companies said they signed a Clinical Trial Collaboration and Supply Agreement to evaluate Amplia’s investigational FAK inhibitor narmafotinib in combination with Eli Lilly’s investigational KRAS G12C therapy olomorasib (marketed as Lumakras in the U.S.), in patients with non-small cell lung cancer.
THE APEX TIMES
Ahead of Eli Lilly’s scheduled earnings report Wednesday morning, options traders are positioning for a move that could carry the stock back toward recent peak levels seen last month.
THE APEX TIMES
Eli Lilly & Co., whose shares have been trading above $1,000 for much of the past few years, is increasingly being viewed by Wall Street as a candidate for a stock split as investor demand remains strong for weight-loss and obesity drug stocks.
THE APEX TIMES
A market-focused note flagged near-term strength in Eli Lilly (LLY) and argued that key developments expected in 2027 could feed through to the stock sooner than some investors may be pricing in.
THE APEX TIMES
Amplia Therapeutics said it has agreed to evaluate its lead drug narmafotinib in combination with Eli Lilly’s next-generation KRAS G12C inhibitor under a clinical collaboration arrangement.
THE APEX TIMES
Eli Lilly said the U.S. Food and Drug Administration has awarded Breakthrough Therapy designation to olomorasib as a single-agent treatment for patients with KRAS G12C-mutant advanced pancreatic cancer, a move investors are watching alongside a reported $70 million financing effort.
